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Abstract                      
Introduction: Escherichia coli (E.coli) as a main cause of both nosocomial and community-
acquired infections in humans have a relative potential to develop resistance. Nowadays, 
most infections caused by ESBL-producing E.coli (ESBLEC) had mostly been described as 
nosocomial acquired or nursing home related. In this study, we employed E-test assay to 
detect antibiotic resistance of E.coli strains and determine MIC of antibiotics. 
Materials and methods: Thirty E.coli strains gathered from Imam Khomeini hospital of 
Ilam, and cultured on TSB and bacterial suspension prepared by 0.5 µF concentration for E-
test. Mueller Hinton agar and E-test strips of Amikacin, Cefepime, Ceftazidime, Ceftriaxone, 
Gentamicin, Meropenem, Nitrofurantoin, Piperacillin/Tazobactam, Tetracycline, Ticarcillin/ 
Clavulanic acid, Tobramycin, Trimethoprim were used  
Results: Resistance to Ceftriaxone, Tobramycin, Gentamicin, Ticarcillin/ Clavulanic, 
Amikacin were 19.8%, 26.4%, 23.3%, 62.7%, 70.3%, respectively. 
Conclusion: the results indicated, E.coli strains in this study were high sensitivity to 
Meropenem ,Nitrofuratoin, Ciprofloxacin , Ceftazidime, Cefepime.  
Keywords: E-test, Antibiotic susceptibility, E.coli, Ilam, Iran 
Introduction 
Escherichia coli (E.coli) as main cause of 
both nosocomial and community-acquired 
infections in humans have a relatively 
large potential for developing resistance 
(1, 2). Urinary tract infection (UTI) is a 
common cause of morbidity in women (3). 
Majority of cases involve only the lower 
urinary tract, and the most common 
pathogen is E.coli (4). UTI result in 
approximately 8 million physician visits 
and more than 100,000 hospital 
admissions per year in the United States 
(5). 
Nowadays, most infections caused by 
ESBL-producing E.coli (ESBLEC) had 
mostly been described as nosocomial 
acquired (6) or nursing home related (7). 
In this study, we recruited E-test assay to 
detect antibiotic resistance of E.coli strains 
and determine MIC of antibiotics. 
Materials and methods 
Sampling: The urine cultures of patients with 
urinary tract infections in Imam Khomeini 
hospital of Ilam were selected. Thirty E.coli 
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isolates after determined by biochemical 
standard tests were used. 
Antibiotic susceptibility testing by E.test 
strip: Antibiogram was performed by Kirby-
Bauer disk diffusion method using Clinical 
Laboratory Standard Institute (CLSI) criteria. 
E.coli isolates was cultured on Muller 
Hinton broth and bacterial suspension 
prepared by 0.5 µF concentration for E-
test. Suspension of bacteria were cultured 
on  Mueller Hinton agar by swab and E-
test strip of amikacin, amoxicillin,  
cefepime, ceftazidime, ceftriaxone, 
gentamicin, meropenem, nitrofurantoin, 
piperacillin/tazobactam, tetracycline, 
ticarcillin/clavulanic acid, tobramycin, 
sulfamethaxazole-trimethoprim were used 
(Table 1). 
Results 
Table 1 shows the MIC of recruited 
antibiotics in this study and Table 2 shows 
result of MIC for isolated strains. 
Table 3 indicated 4(13.33%) strains were 
resistance, 8(26.66%) strains were 
intermediate and other strains were 
susceptible for TX. 3(10%) of strains were 
resistance, 13(43.33%) were intermediate 
and other were susceptible for TM . 
2(6.66%) were resistance to MP. 
4(13.33%) were resistance, 10 (33.33%) 
were intermediate to TZ but other strains 
shown susceptibility pattern. 3(10%) 
strains were resistance to GM. All of 
strains shown susceptibility toVA and LZ.
 
Table 1. Utilized antibiotics in this study. 
µg/ml Quality Control S≤       I       R≥ Code 
ANTIBIOTIC 
µg/ml 
1.4 
 
E.coli         ATCC25922 
 
16      32     64 AK 
amikacin 
0.016-256 
0.016-0.064 
 
E.coli         ATCC25922 
 
8      16       32 
 
PM 
cefepime 
0.002-32 or 
0.016-256 
0.064-0.5 
0.5-2 
0.125-1 
E.coli         ATCC25922 
P.aeruginosa  ATCC27853 
H.influenzae  ATCC49247 
8       16      32 
2        -          - 
TZ 
ceftazidime 
0.016-256 
0.032-0.125 
 
E.coli         ATCC25922 
 
8   16-32    64 
 
TX 
ceftriaxone 
0.002-32 or 
0.016-256 
0.25-1 
 
E.coli         ATCC25922 
 
4       8       16 GM 
gentamicin 
0.016-256 
0.008-0.64 
 
E.coli         ATCC25922 
 
4       8       16 
 
MP 
meropenem 
0.002-32 
4-16 E.coli         ATCC25922 32     64   128 NI 
nitrofurantoin 
0.032-512 
1-4 
 
E.coli         ATCC25922 
 
16  32-16 128 PTC 
piperacillin/ 
tazobactam 
0.016-256 
0.5-2 
 
E.coli         ATCC25922 
 
2        4        8 
 
TC 
tetracycline 
0.016-256 
2-8 
 
E.coli         ATCC25922 
 
16  32-16 128 
 
TLC 
ticarcillin/ 
clavulanic acid 
0.016-256 
0.125-1 
 
E.coli         ATCC25922 
 
4       8       16 
 
TM 
tobramycin 
0.016-
256or0.064-1024 
0.064-0.25 
 
E.coli         ATCC25922 
 
2        -        4 
 
TS 
trimethoprim 
0. 002-32 
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Table 2. MIC results for E.coli strains by E-test (µg/ml). 
TZ MP AC TX NI PM TLC TS CI PTC TC AK TM GM 
Antibiotic 
 
 
Strain 
0.125 0.064 256 0.016 0.19 0.5 256 0.25 32 2 256 1 0.19 0.125 1 
0.125 0.032 256 0.016 0.094 0.25 256 1 32 2 256 32 0.096 0.096 2 
0.094 0.023 2 0.032 0.75 0.125 1.5 0.064 6 1 2 0.75 0.5 0.125 3 
256 0.032 256 256 256 256 256 0.064 32 1.5 256 1 16 0.064 4 
0.25 .25 256 0.25 0.125 0.19 256 32 32 4 256 1 0.25 0.25 5 
0.094 0.016 256 0.5 0.125 0.047 256 32 32 1 256 0.25 4 8 6 
0.094 0.016 4 0.125 8 0.023 8 0.19 8 1 2 0.25 0.19 0.5 7 
2 0.094 256 2 256 1 256 32 32 0.75 256 1 0.19 0.5 8 
0.094 0.012 64 256 4 0.094 256 0.125 32 0.75 256 1 0.25 0.25 9 
256 0.032 96 0.19 8 0.094 4 1 32 2 256 1.5 0.19 0.25 10 
0.125 0.125 4 1 1 0.094 2 0.25 24 1 8 2 32 96 11 
8 0.016 256 8 2 3 256 0.5 32 4 256 1.5 12 16 12 
8 0.064 256 4 8 2 256 32 32 1 256 1.5 1.5 0.125 13 
2 0.094 256 256 64 0.032 256 0.5 32 256 256 1.5 0.032 0.064 14 
16 0.047 16 256 24 256 32 0.25 32 8 256 2 64 192 15 
0.5 0.023 256 1 8 0.125 8 0.19 6 4 6 0.064 0.25 0.38 16 
0.25 0.012 4 0.125 16 0.125 6 0.064 32 1 256 0.047 0.19 0.25 17 
8 0.094 64 8 8 4 32 0.25 32 16 256 1.5 12 24 18 
0.5 0.012 12 256 0.5 0.125 256 0.19 32 4 2 0.25 0.25 0.125 19 
4 0.023 64 0.125 16 0.125 256 1 32 4 256 0.19 0.19 0.19 20 
48 0.023 256 0.032 16 0.032 256 0.094 32 4 256 1.5 1.5 0.125 21 
0.125 0.047 4 1.5 16 1 12 0.19 32 1 256 32 64 96 22 
0.125 0.023 256 256 8 256 256 0.125 32 1 1.5 2 0.064 0.064 23 
8 0.032 256 0.032 4 0.032 256 0.5 32 24 256 6 2 2 24 
8 0.094 256 12 2 4 256 0.064 1 24 1 1.5 48 48 25 
1 0.047 256 1 4 1 256 0.125 32 8 256 6 32 48 26 
0.032 0.032 256 0.032 32 32 256 0.064 4 2 4 1.5 1 1 27 
1 0.016 256 4 2 2 256 0.25 32 2 256 0.25 0.25 0.094 28 
0.094 0.016 64 0.25 1 0.064 3 31 32 0.75 256 1.5 0.25 0.19 29 
0.064 0.023 256 0.75 0.25 0.023 8 1 2  1.5 1 0.024 0.064 30 
20.88 0.047 166.86 52.57 25.53 27.33 164.95 5.60 
26.2
3 
13.16 180.13 9.77 3.45 18.57 Mean  
AK; amikacin, AM; amoxicillin, PM; cefepime, TZ; ceftazidime, TX; ceftriaxone, GM; 
gentamicin, MP: meropenem ,NI; nitrofurantoin, PCT; piperacillin/tazobactam,TC; 
tetracycline, TLC; ticarcillin/clavulanic acid, TM; tobramycin, SXT; sulfamethaxazole-
trimethoprim, CI; ciprofloxacin, AC; ampcillin/cloxacillin. 
  
 Table 3. Antibiogram result of E.coli strains. 
R I S Antibiotic 
19.8 - 70.2 Ceftriaxone  
26.4 - 72.6 Tobramycin  
- - 100 Meropenem  
6.6 - 93.4 Ceftazidime 
23.3 3.3 73.3 Gentamicin  
62.7 6.6 29.7 Ticarcillin/Clavulanic acid  
6.6 3.3 90.1 Nitrofurantoin  
16.5 - 83.5 Trimethoprim 
3.3 6.6 90.1 Piperacillin/Tazobactam  
70.3 6.6 23.1 Amikacin 
16.6 - 83.3 Tetracycline  
76.6 3.3 20 Ciprofloxacin  
9.9 - 90.1 Cefepime 
83.3 13.3 3.3 Ampcillin/Cloxacillin  
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Discussion 
Nowadays, around the world there is 
increasing antibiotic resistance among 
bacterial infection, especially in hospital 
wards such as ICU therefore antibiotic 
resistance pattern determine as main issue 
is considered to treat infection.  In this 
cross-sectional study, 30 strains of E.coli 
isolated from Ilam hospitals. Our results 
indicated E.coli is resistance to 
Amoxicillin, Tetracycline by 82.5% and 
62.7% in row. Also, E.coli shown 
susceptibility to Meropenem, Ceftazidime, 
Cefepime, Nitrofurantoin, and Piperacillin 
by 100%, 93.4%, and 90.1%, respectively.  
Most susceptibility was to Meropenem, 
Ceftazidime, Cefepime, Nitrofurantoin and 
Piperacillin and lower susceptibility were 
to Amoxicillin and Tetracycline . 
Azar Hadadi and colleague study result 
confirm our results and shown E.coli 
susceptibility to Imipenem, Ceftriaxone 
and Ceftazidime were 91%, 21% and 21% 
(8).  
Zohre Torabi study on isolated E.coli form 
UTI indicated among 118 E.coli resistance 
to Ampicillin and Cefexime were 86.2% 
and 73.6% in row.  In this study 
Ciprofloxacin was most effective 
antibiotic in all wards of hospital to 
eliminate Urinary Tract Infection. 
Nitrofurantoin, Ceftriaxone and Amikacin 
by 51.9%, 44.4% and 8.4% resistance 
were in followed row (9). 
Conclusion 
Regarding to microbial resistance 
increasing in hospitals, there is need to 
collaboration between committee of 
antibiotic prescribe and infection control 
committee. To achieve this result, there is 
need to establish surveillance system in 
hospital that study microorganism 
prevalence and their resistance pattern in 
hospitals. 
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